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The incidence of end-stage kidney disease (ESKD) is up to 15 times higher in Indigenous than 
non-Indigenous Australians1, 2, with the burden of ESKD in Indigenous Australians borne 
disproportionately by those in central and northern Australia.3 This group of people is widely 
dispersed and heterogeneous, with wide variation in diet, body habitus, ethnic admixture and 
socioeconomic background.4, 5 Aboriginal Australians traditionally had a ‘linear’ body build 
(narrow across the shoulders and hips, relatively long limbs and short torso), which in contrast to 
African Americans is associated with proportionately less muscle and more fat for a given 
weight.4, 6 We hypothesised that: (i) the African American correction factor in estimated 
Glomerular Filtration Rate (eGFR) equations should not be used in Indigenous Australians; and 
(ii) differences in body build and body composition in Indigenous Australians will affect the 
utility of creatinine-based estimated measures of GFR. The aim of “The eGFR Study” was 
therefore to validate and improve if necessary the accuracy and precision of eGFR equations in 
Indigenous Australians. 
 
The methods (Item S1) have been previously described in detail8. Participants were Indigenous 
Australians aged 18 years and above, recruited from urban, rural and remote centres within four 
geographical regions of Australia across five pre-defined strata of health, diabetes status and 
kidney function. A comparator group of Caucasian Australians was recruited from Darwin, 
Northern Territory, Australia. GFR was measured (mGFR) using an iohexol plasma 
disappearance technique over 4 hours. Estimates of GFR were calculated using the MDRD-4 and 
CKD-EPI equations9. Data analysis was performed using STATA v10.0 (Stata Corporation, TX, 
USA). 
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When compared to Caucasian participants, Indigenous participants were younger, with higher 
rates of albuminuria, diabetes and cigarette smoking (Table 1). Indigenous participants had equal 
or higher levels of eGFR and mGFR than Caucasians. 
 
In Indigenous participants (Figure 1), use of the African American correction factor resulted in 
overestimation of GFR using both MDRD-4 and CKD-EPI equations. Without the African 
American correction factor, the median bias was greater using the MDRD-4 equation (8.9 
[95%CI, 7.9 to 11.1] below mGFR) than with use of the CKD-EPI equation (3.8 [95% CI, 2.5 to 
5.6] below mGFR). When stratified by mGFR group (Table S1), bias was highest in Indigenous 
participants with mGFR≥90mls/min/1.73m2 when the MDRD-4 equation was used but improved 
with use of the CKD-EPI equation (without the correction factor). Accuracy of eGFR was not 
significantly different between use of MDRD-4 or CKD-EPI equations, for Indigenous and 
Caucasian participants.  
 
Thus, we report that the magnitude of bias using the MDRD-4 equation in Indigenous 
participants was similar with or without use of the African American correction factor for 
Indigenous Australians, however the direction of bias differed, such that GFR was overestimated 
with use of the correction factor and underestimated without it. For the CKD-EPI equation, bias 
and accuracy were significantly improved with omission of the correction facotr.  
 
With omission of African American correction factor, eGFR using the CKD-EPI equation 
provided a reasonably unbiased and accurate estimate of GFR, while the MDRD-4 equation 
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resulted in significant underestimation of GFR in Indigenous Australians (compared to a 
Caucasian Australian comparator group). This may relate to inherent limitations of the MDRD-4 
equation rather than body build or other differences in Indigenous Australians. The CKD-EPI 
equation has been shown to perform better at higher mGFRs (approximately >60ml/min/1.73m2) 
and the MDRD performs better at lower GFRs.10 The mean mGFR of the Indigenous Australian 
cohort (93 ml/min/1.73m2) was closer to that of the CKD-EPI than MDRD development cohort 
and this most likely explains why the CKD-EPI equation performed better than the MDRD-4 
equation.7, 9 Heterogeneity and ethnic admixture among the Indigenous Australian population 
makes the application of a single accurate correction factor for Indigenous Australians in the 
eGFR equation unlikely and impractical. Similar concerns about the limitations of the race 
coefficient used in North America have been recently raised.11 
 
A potential limitation of our study is the use of iohexol clearance as the formal GFR 
measurement.8 The study was designed with respect to what is practical and achievable in very 
remote regions of Australia. Collection over a time period longer than 4 hours was not practical, 
and this may explain reduced accuracy of eGFR in participants with reduced GFR.12 The 
Indigenous and Caucasian Australian groups were not able to be matched for key factors such as 
age, GFR, diabetes diagnosis and albuminuria (due to population differences such as younger 
age of onset of chronic diseases and higher prevalence of diabetes as a comorbidity among 
Indigenous Australians with ESKD). However the Caucasian group was not intended to be a 
matched group, but a group in which the performance of eGFR equations could be assessed in 
comparison to other studies from North America, Europe and Australia, thereby supporting the 
reference GFR methodology used in the current study. Participants were volunteers, recruited 
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across five strata of health, diabetes status and kidney function, and we are unable to comment 
on how representative they are of their respective communities and ethnic groups. The majority 
of participants did not have CKD. 
 
In conclusion, eGFR using the CKD-EPI equation (without the African American correction 
factor) provides a reasonably unbiased and accurate estimate of GFR in Indigenous Australians. 
These results support the proposed change to use of the CKD-EPI equation for routine reporting 
of eGFR in Australia.13 
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Table 1: Characteristics of Participants. Data are mean + standard deviation or n (%). 
 All Participants Group 1: GFR<60 Group 2: GFR 60-89 Group 3: GFR≥90 p values 
 Indigenous 
Australian 
Caucasian 
Australian 
Indigenous 
Australian 
Caucasian 
Australian 
Indigenous 
Australian 
Caucasian 
Australian 
Indigenous 
Australian 
Caucasian 
Australian 
Ethn-
icity 
GFR 
group 
n 576 99 72 20 115 32 389 47   
Age (yrs) 45 + 15 54 + 14 59 + 12 62 + 14 53 + 13 61 + 11 40 + 12 47 + 13 <0.001 <0.001 
Male* 217 (38%) 45 (45%) 23 (32%) 14 (70%) 43 (37%) 14 (44%) 151 (39%) 17 (36%) 0.194 0.530 
Height (cm) 167 + 8 169 + 8 164 + 7† 171 + 9 167 + 8 170 + 8 167 + 8 168 + 8 - - 
Weight(kg) 83 + 21 83 + 18 78 + 21 84 + 19 81 + 23 84 + 16 85 + 20 82 + 19 0.879 0.029 
BMI(kg/m2) 30.0 + 7.2 29.0 + 5.7 28.9 + 7.4 29.0 + 6.0 29.1 + 7.7 29.1 + 5.4 30.5 + 6.9 29.0 + 5.9 0.337 0.117 
Waist (cm) 101 + 16 98 + 17 102 + 15 103 + 18 100 + 17 99 + 15 101 + 16 95 + 18 0.156 0.365 
WHR 0.94 +0.09 0.92 +0.11 0.98 +0.09 0.99 +0.11 0.94 +0.10 0.93 +0.10 0.93 +0.09 0.89 +0.11 0.058 <0.001 
Microalb-
uminuria 
101 (18%) 10 (10%) 13 (19%) 5 (25%) 21 (20%) 2 (6%) 67 (18%) 3 (7%) 0.001 <0.001 
Macroalb-
uminuria 
116 (21%) 11 (11%) 48 (72%) 8 (40%) 26 (24%) 2 (6%) 42 (11%) 1 (2%) <0.001 <0.001 
Diabetes 234 (41%) 26 (26%) 51 (73%) 9 (45%) 53 (46%) 10 (31%) 130 (34%) 7 (15%) 0.002 <0.001 
Current 
smoker 
239 (42%) 12 (12%) 18 (25%) 0 33 (29%) 4 (13%) 188 (48%) 8 (17%) <0.001 <0.001 
Creatinine 
(umol/L)* 
75 
(72-77) 
85 
(77-93) 
156 
(139-175) 
177 
(145-216) 
80 
(76-84) 
75 
(70-81) 
64 
(63-66) 
67 
(63-72) 
0.002 - 
eGFR 
(MDRD) 
82 
(79-86) 
70 
(63-77) 
33 
(29-37) 
31 
(25-39) 
73 
(70-77) 
78 
(72-84) 
101 
(99-104) 
92 
(87-98) 
<0.001 - 
eGFR 
(MDRDbl) 
100 
(96-104) 
70 
(63-77) 
40 
(35-45) 
31 
(25-39) 
89 
(85-93) 
78 
(72-84) 
123 
(120-125) 
92 
(87-98) 
<0.001 - 
eGFR 
(CKD-EPI)* 
88 
(85-92) 
76 
(69-84) 
36 
(31-41) 
33 
(26-41) 
83 
(79-86) 
85 
(79-91) 
107 
(105-108) 
100 
(96-105) 
0.001 - 
eGFR 
(CKD-EPIbl) 
103 
(99-106) 
76 
(69-84) 
42 
(36-48) 
33 
(26-41) 
96 
(92-100) 
85 
(79-91) 
123 
(122-125) 
100 
(96-105) 
<0.001 - 
mGFR 93 
(89-96) 
76 
(69-83) 
37 
(33-41) 
34 
(28-41) 
78 
(76-80) 
78 
(75-81) 
116 
(114-117) 
105 
(101-109) 
<0.001 - 
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GFR data are presented as ml/min/1.73m2. Groups defined according to mGFR. 
p values refer to overall differences across groups using analysis of variance (continuous variables) and logistic regression models 
(categorical variables). Comparison group for microalbuminuria and macroalbuminuria is participants with normoalbuminuria. 
Comparison of creatinine, eGFR and mGFR was performed only between all Indigenous and Caucasian participants, not by mGFR 
strata. 
†p<0.05 compared to Caucasian group of same mGFR group for variables where there was a significant interaction between ethnicity and 
mGFR group. 
Significant interaction between ethnicity and mGFR group for height only (p=0.027). 
eGFR, estimated glomerular filtration rate; BMI, body mass index; WHR, waist-hip ratio; ACR, albumin-creatinine ratio. 
*log transformed. 
eGFR, estimated glomerular filtration rate; mGFR, measured glomerular filtration rate; MDRD, Modification of Diet in Renal 
Disease; MDRDbl, MDRD with Afircan American correction factor; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration, 
CKD-EPIbl, CKD-EPI with African American correction factor. 
Diabetes was defined as a previous diagnosis of diabetes or HbA1c≥6.5%. Microalbuminuria was defined as urine ACR ≥2.5 and ≤25 
mg/mmol  in men and ≥3.5 and ≤25 mg/mmol in women. Macroalbuminuria was defined as ACR > 25mg/mmol.  
Number of participants with missing data:  
eGFR<60: Indigenous, waist (4), WHR (4), urine ACR (5), diabetes (2), smoking (1). 
eGFR 60-89: Indigenous, waist (1), WHR (2), urine ACR (8), diabetes (1), smoking (3). 
eGFR≥90: Indigenous, waist (17), WHR (19), urine ACR (12), diabetes (4), smoking (1); Caucasian, waist (1), WHR (1), urine ACR 
(2). 
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Figure 1: Differences between reference and estimated glomerular filtration rate (GFR), for  
estimating equations, according to the level of estimated GFR, by ethnicity. 
 
Caucasian participants (■), Indigenous participants (○). Dashed lines eGFR +/- 30% different 
from mGFR. The +/- 30% lines are not evenly spaced above and below the x-axis as they 
indicate percent difference relative to mGFR rather than eGFR which is used on the x-axis.  
 
A: MDRD (without African American correction factor) 
Median bias: Caucasian, 3.4 (-0.2, 6.3); Indigenous, 8.9 (7.9, 11.1). 
Accuracy (P30): Caucasian, 87 (79-93); Indigenous, 85 (82-88). 
 
B: CKD-EPI (without African American correction factor) 
Median bias: Caucasian, -1.9 (-5.5, 1.4); Indigenous, 3.8 (2.5, 5.6). 
Accuracy (P30): Caucasian, 87 (79-93); Indigenous, 88 (85-90). 
 
C: MDRD (with African American correction factor) 
Median bias: Caucasian, 3.4 (-0.2, 6.3); Indigenous, -8.3 (-10.0, -5.7). 
Accuracy (P30): Caucasian, 87 (79-93); Indigenous, 81 (78-84). 
 
D: CKD-EPI (with African American correction factor) 
Median bias: Caucasian, -1.9 (-5.5, 1.4); Indigenous, -10.4 (-11.9, -8.0). 
Accuracy (P30): Caucasian, 87 (79-93); Indigenous, 79 (75-82). 
 
Table S1: Comparison of performance of eGFR (MDRD and CKD-EPI) to reference GFR in 
different ethnic groups 
 
Item S1: online supplementary methods 
 
